Merck & Co., Inc. (BVL:MRK)

Market Cap	1.01T +7.9%
Revenue (ttm)	218.71B +1.3%
Net Income	61.41B +6.6%
EPS	24.49 +8.0%
Shares Out	n/a
PE Ratio	16.46
Forward PE	23.61
Dividend	11.57 (9.56%)
Ex-Dividend Date	Dec 15, 2025

Volume	n/a
Average Volume	84
Open	n/a
Previous Close	121.06
Day's Range	n/a
52-Week Range	73.98 - 121.06
Beta	n/a
RSI	84.82
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Pharmaceutical Preparations
• Founded: 1891
• Employees: 74,000
• Stock Exchange: Lima Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.

Financial numbers in USD